+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Therapeutic Drug Monitoring Market by Product Type, Technology, End User, Drug Class, Application - Global Forecast to 2030

  • PDF Icon

    Report

  • 186 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5367869
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Therapeutic Drug Monitoring Market grew from USD 4.38 billion in 2024 to USD 5.11 billion in 2025. It is expected to continue growing at a CAGR of 16.21%, reaching USD 10.80 billion by 2030.

Setting the Stage for Precision Therapeutic Monitoring

Therapeutic drug monitoring has emerged as a critical component of personalized medicine, enabling clinicians to fine-tune dosing regimens and achieve optimal therapeutic outcomes. As treatment paradigms evolve toward precision care, the ability to accurately measure drug concentrations and adapt therapy in real time becomes ever more essential. Beyond dose optimization, robust monitoring frameworks mitigate adverse events, reduce hospitalizations, and support regulatory compliance across diverse clinical settings.

This executive summary delivers a comprehensive overview of the current therapeutic drug monitoring landscape, spotlighting the technological breakthroughs, regulatory shifts, and market forces shaping the industry. It examines the recent imposition of U.S. tariffs and their cascading effects on instrument prices, reagent supply chains, and laboratory budgets. The narrative then navigates through key segmentation insights, revealing where demand concentrates by product type, technological approach, end-user setting, drug class, and clinical application.

By weaving together regional analyses, competitive profiles of leading innovators, and rigorous research methodology, this summary arms decision-makers with the strategic context needed to thrive in a complex global market. The insights presented herein prioritize clarity, relevance, and actionable intelligence, laying the groundwork for informed investments and agile responses to emerging opportunities and challenges.

Unveiling Transformative Trends Reshaping TDM

In recent years, therapeutic drug monitoring has undergone a profound transformation driven by advances in analytical instrumentation and digital integration. The maturation of mass spectrometry platforms has elevated sensitivity and specificity to new heights, enabling simultaneous quantification of multiple analytes with unprecedented accuracy. At the same time, point-of-care immunoassay devices now offer near-real-time feedback in decentralized settings, empowering clinicians to adjust therapies on the spot.

Regulatory frameworks are also evolving, with agencies worldwide refining guidelines to endorse the adoption of advanced monitoring techniques. Harmonization initiatives aim to reduce variability across laboratories, while quality-control mandates ensure reproducibility and patient safety. These policy developments are complemented by the rise of software-driven data management tools that streamline workflow, automate result interpretation, and facilitate remote oversight.

Looking ahead, the convergence of artificial intelligence, machine learning, and large-scale clinical datasets promises to unlock predictive dosing models. These capabilities will enable proactive adjustments, minimize trial-and-error dosing, and enhance patient adherence through personalized digital engagement. As stakeholders embrace integrated ecosystems that link instrumentation, reagents, software, and services, therapeutic drug monitoring stands at the cusp of a new era defined by precision, speed, and clinical impact.

Assessing the 2025 Tariff Ripple Effects in the US

In 2025, the implementation of new U.S. tariffs on imported analytical instruments and reagents has introduced significant cost pressures across the therapeutic drug monitoring value chain. Applied duties on chromatography systems, mass spectrometry modules, and associated consumables have elevated capital expenditure requirements for laboratory operators. As a result, many facilities are reevaluating procurement strategies to mitigate budgetary constraints.

The upward pricing pressure extends to reagent kits and mass spectrometry supplies, squeezing margins for both manufacturers and end users. Laboratories reliant on highly standardized immunoassay kits find themselves negotiating increasingly complex supply agreements to preserve continuity of care. In response, equipment vendors are exploring alternative sourcing strategies, such as near-shoring and regional manufacturing partnerships, to stabilize lead times and control costs.

Beyond immediate cost implications, trade policy uncertainty has amplified risk considerations in long-term planning. Organizations are intensifying scenario analyses to quantify the impact of prolonged tariffs on capital planning, reagent inventory management, and service contract structures. This heightened focus on supply chain resilience underscores the importance of strategic flexibility and the pursuit of diversified procurement channels in a dynamic trade environment.

Decoding Market Segmentation for Strategic Clarity

A nuanced understanding of therapeutic drug monitoring requires dissecting the market through multiple segmentation lenses. When viewed by product type, the landscape encompasses precision instrumentation, consumable reagents and kits, and specialized software and services. Instrumentation divides into immunoassay analyzers renowned for rapid throughput, liquid chromatography systems prized for chromatographic resolution, and mass spectrometry systems that deliver unmatched analytical depth. Complementing these are immunoassay kits designed for targeted biomarker detection, liquid chromatography reagents that bolster separation fidelity, and mass spectrometry reagents optimized for ionization efficiency. Consulting services and data management software further enrich this ecosystem by facilitating system integration, result interpretation, and workflow optimization.

Technological segmentation reveals distinct avenues of innovation. Chromatography is bifurcated into gas and liquid modalities, each addressing specific compound classes and throughput needs. Immunoassay methodologies span CLIA-certified assays, ELISA protocols, and FIA techniques, offering diverse sensitivity and specificity profiles. Mass spectrometry has evolved into single quadrupole platforms for routine quantitation and tandem configurations for complex, multi-analyte assessments.

End users vary from centralized clinical laboratories to home healthcare settings, academic research institutes, and large hospital networks. This distribution reflects the need for flexible monitoring solutions that align with the workflow and regulatory environment of each setting. Drug class segmentation highlights antibiotics, anticancer therapies, antiepileptic regimens, cardiovascular treatments, and immunosuppressant protocols. Within immunosuppressants, antimetabolites, calcineurin inhibitors, and mTOR inhibitors represent critical categories requiring rigorous concentration control. Finally, applications encompass cardiology, infectious disease management-addressing bacterial, fungal, and viral infections-neurology, oncology subsegments such as leukemia and solid tumors, and post-transplantation monitoring.

Uncovering Regional Dynamics Driving Market Growth

Regional dynamics play a pivotal role in shaping the adoption and evolution of therapeutic drug monitoring solutions. In the Americas, robust healthcare infrastructure and high per-capita healthcare spending drive accelerated uptake of advanced mass spectrometry and immunoassay platforms. Market leaders leverage strong reimbursement frameworks and extensive research collaborations to pioneer integrated monitoring protocols that set global benchmarks.

In Europe, the Middle East, and Africa, a diverse regulatory landscape influences deployment strategies. Western European countries benefit from harmonized guidelines that facilitate cross-border data sharing, whereas emerging markets in the Middle East and Africa exhibit rapid growth potential fueled by investments in diagnostic capacity and public health initiatives. This region’s heterogeneity presents both challenges in standardization and opportunities for targeted solutions that address local disease burdens and regulatory requirements.

Across Asia-Pacific, surging prevalence of chronic conditions and expanding healthcare budgets underpin a surge in demand for both centralized laboratory services and point-of-care diagnostic devices. Governments in key markets are prioritizing precision medicine initiatives, driving collaborations between global instrument manufacturers and domestic research institutes. The result is a dynamic landscape where innovation partnerships and scalable deployments define competitive advantage.

Mapping Key Industry Players and Strategic Moves

The competitive tableau of therapeutic drug monitoring is defined by a mix of established instrument providers and emerging technology firms. Global leaders in mass spectrometry instrumentation maintain commanding positions with continuous platform enhancements that elevate sensitivity thresholds and streamline user workflows. At the same time, established immunoassay vendors capitalize on broad reagent libraries and integrated analyzer-kit ecosystems that simplify implementation for clinical laboratories.

Strategic alliances and acquisitions have accelerated technology convergence, with chromatography specialists acquiring software developers to embed advanced data analytics into their offerings. Meanwhile, contract research organizations and consulting firms have expanded their service portfolios to support end-to-end monitoring solutions, from method development to regulatory submission assistance. In parallel, nimble startups are challenging incumbents by introducing AI-driven assay validation and cloud-based result management platforms.

The interplay between these players shapes pricing dynamics, innovation roadmaps, and global distribution networks. Leading companies differentiate through comprehensive post-market support, training programs, and partnerships that ensure seamless integration with hospital information systems. Observing these strategic moves provides critical foresight into where competitive pressures will intensify and which capabilities will define market leadership.

Actionable Strategies to Navigate Future Market Challenges

Industry leaders seeking to capitalize on the therapeutic drug monitoring opportunity should prioritize investment in modular platforms that accommodate both chromatography and mass spectrometry workflows. Integrating analytics software that leverages machine learning for predictive dosing models will deliver tangible clinical value and bolster adoption in precision medicine programs. Cultivating partnerships with reagent specialists and academic centers can accelerate method validation and regulatory approvals, reducing time to market for novel assays.

To counteract tariff-driven cost volatility, organizations must diversify their manufacturing and procurement strategies. Establishing regional production facilities or collaborating with local partners can insulate supply chains from future trade disruptions. Simultaneously, expanding decentralized testing capabilities through portable immunoassay devices and home-based monitoring solutions will broaden market reach and improve patient adherence.

Finally, embedding sustainability principles into product design and service delivery not only addresses growing environmental concerns but also enhances corporate reputation. By adopting eco-friendly consumables, optimizing energy efficiency in instrumentation, and offering digital training resources, companies can align with broader healthcare greening initiatives. This combined approach of technological innovation, supply chain resilience, and environmental stewardship will position industry leaders to navigate emerging challenges and secure long-term growth.

Rigorous Methodology Underpinning Research Validity

This research employed a hybrid methodology combining rigorous primary and secondary data collection processes. Primary insights were garnered through structured interviews with laboratory directors, procurement managers, and chief medical officers across North America, Europe, and Asia-Pacific. These conversations elucidated decision-making criteria, budgetary constraints, and emerging clinical requirements.

Secondary research drew on peer-reviewed journals, regulatory filings, patent databases, and corporate financial disclosures to establish a robust contextual foundation. Trade data and tariff schedules were analyzed to quantify cost impacts, while market intelligence platforms provided historical shipment and pricing trends. Data triangulation techniques ensured that quantitative findings aligned with qualitative stakeholder perspectives.

Analytical rigor was maintained through statistical modeling of instrument lifecycle costs, scenario analysis of trade policy shifts, and sensitivity testing across segmentation variables. All data sources underwent validation checks, and any discrepancies were reconciled through follow-up interviews and vendor consultations. This systematic approach underpins the reliability and actionable relevance of the insights presented.

Concluding Insights and Market Imperatives

Therapeutic drug monitoring stands at an inflection point where technological innovation, regulatory evolution, and global trade policies converge to shape market trajectories. This summary has highlighted transformative trends-from mass spectrometry advancements to integrated digital platforms-while examining the financial and operational reverberations of newly imposed tariffs.

By dissecting the market through product, technology, end-user, drug class, and application lenses, decision-makers gain a granular view of demand drivers and competitive hotspots. Regional analyses further contextualize growth pathways, revealing where strategic investments can yield the greatest return. Profiles of leading industry players illuminate the tactics that drive differentiation and market share expansion.

Collectively, these insights underscore the imperative for agile strategies that embrace modular innovation, supply chain diversification, and sustainability. As therapeutic drug monitoring continues to underpin personalized treatment paradigms, organizations equipped with data-driven foresight will be best positioned to deliver improved patient outcomes and sustainable business performance.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Instruments
      • Immunoassay Analyzers
      • Liquid Chromatography Systems
      • Mass Spectrometry Systems
    • Reagents & Kits
      • Immunoassay Kits
      • Liquid Chromatography Reagents
      • Mass Spectrometry Reagents
    • Software & Services
      • Consulting Services
      • Data Management Software
  • Technology
    • Chromatography
      • Gas Chromatography
      • Liquid Chromatography
    • Immunoassay
      • Clia
      • Elisa
      • Fia
    • Mass Spectrometry
      • Single Quadrupole Mass Spectrometry
      • Tandem Mass Spectrometry
  • End User
    • Clinical Laboratories
    • Home Healthcare
    • Hospitals
    • Research Institutes
  • Drug Class
    • Antibiotics
    • Anticancer Drugs
    • Antiepileptics
    • Cardiovascular Drugs
    • Immunosuppressants
      • Antimetabolites
      • Calcineurin Inhibitors
      • Mtor Inhibitors
  • Application
    • Cardiology
    • Infectious Disease
      • Bacterial Infections
      • Fungal Infections
      • Viral Infections
    • Neurology
    • Oncology
      • Leukemia
      • Solid Tumors
    • Transplantation
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • Abbott Laboratories
  • Danaher Corporation
  • Siemens Healthineers AG
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Eurofins Scientific SE
  • Charles River Laboratories International, Inc.
  • ARKRAY, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Therapeutic Drug Monitoring Market, by Product Type
8.1. Introduction
8.2. Instruments
8.2.1. Immunoassay Analyzers
8.2.2. Liquid Chromatography Systems
8.2.3. Mass Spectrometry Systems
8.3. Reagents & Kits
8.3.1. Immunoassay Kits
8.3.2. Liquid Chromatography Reagents
8.3.3. Mass Spectrometry Reagents
8.4. Software & Services
8.4.1. Consulting Services
8.4.2. Data Management Software
9. Therapeutic Drug Monitoring Market, by Technology
9.1. Introduction
9.2. Chromatography
9.2.1. Gas Chromatography
9.2.2. Liquid Chromatography
9.3. Immunoassay
9.3.1. Clia
9.3.2. Elisa
9.3.3. Fia
9.4. Mass Spectrometry
9.4.1. Single Quadrupole Mass Spectrometry
9.4.2. Tandem Mass Spectrometry
10. Therapeutic Drug Monitoring Market, by End User
10.1. Introduction
10.2. Clinical Laboratories
10.3. Home Healthcare
10.4. Hospitals
10.5. Research Institutes
11. Therapeutic Drug Monitoring Market, by Drug Class
11.1. Introduction
11.2. Antibiotics
11.3. Anticancer Drugs
11.4. Antiepileptics
11.5. Cardiovascular Drugs
11.6. Immunosuppressants
11.6.1. Antimetabolites
11.6.2. Calcineurin Inhibitors
11.6.3. Mtor Inhibitors
12. Therapeutic Drug Monitoring Market, by Application
12.1. Introduction
12.2. Cardiology
12.3. Infectious Disease
12.3.1. Bacterial Infections
12.3.2. Fungal Infections
12.3.3. Viral Infections
12.4. Neurology
12.5. Oncology
12.5.1. Leukemia
12.5.2. Solid Tumors
12.6. Transplantation
13. Americas Therapeutic Drug Monitoring Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Therapeutic Drug Monitoring Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Therapeutic Drug Monitoring Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. F. Hoffmann-La Roche Ltd.
16.3.2. Thermo Fisher Scientific Inc.
16.3.3. Abbott Laboratories
16.3.4. Danaher Corporation
16.3.5. Siemens Healthineers AG
16.3.6. Agilent Technologies, Inc.
16.3.7. Bio-Rad Laboratories, Inc.
16.3.8. Eurofins Scientific SE
16.3.9. Charles River Laboratories International, Inc.
16.3.10. ARKRAY, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. THERAPEUTIC DRUG MONITORING MARKET MULTI-CURRENCY
FIGURE 2. THERAPEUTIC DRUG MONITORING MARKET MULTI-LANGUAGE
FIGURE 3. THERAPEUTIC DRUG MONITORING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. THERAPEUTIC DRUG MONITORING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. THERAPEUTIC DRUG MONITORING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. THERAPEUTIC DRUG MONITORING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY LIQUID CHROMATOGRAPHY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY MASS SPECTROMETRY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAY KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY LIQUID CHROMATOGRAPHY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY MASS SPECTROMETRY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY GAS CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY LIQUID CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CLIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ELISA, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY FIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SINGLE QUADRUPOLE MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TANDEM MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTICANCER DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIEPILEPTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CARDIOVASCULAR DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 93. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 94. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 95. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 96. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 97. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 98. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 99. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 100. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 101. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 103. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 104. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 105. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 106. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 107. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 108. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 109. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 110. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 111. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 112. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 113. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 114. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 115. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 116. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 117. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 118. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 119. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 120. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 143. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 145. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 146. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 147. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 148. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 164. UNITED KINGDOM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 166. UNITED KINGDOM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 168. UNITED KINGDOM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 170. UNITED KINGDOM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 172. UNITED KINGDOM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 174. UNITED KINGDOM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 176. UNITED KINGDOM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 178. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 179. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 180. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 181. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 182. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 183. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 184. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 185. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 186. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 188. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 189. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 190. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 191. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 192. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 193. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 194. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 195. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 196. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 197. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 198. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 199. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 200. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 202. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 203. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 204. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 205. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 206. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 207. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 208. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 209. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 210. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 211. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 212. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 213. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 214. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 215. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 216. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 217. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 218. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 219. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 220. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 221. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 222. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 223. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 224. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 225. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 226. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 227. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 228. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 230. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 231. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 232. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 233. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 234. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 235. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 236. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 237. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 238. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 239. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 240. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 241. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 242. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 244. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 245. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 246. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 247. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 248. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 259. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 260. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 261. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 262. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 264. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 266. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 268. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 270. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 272. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 274. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 276. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 278. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 280. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 282. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 283. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 284. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 285. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 286. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 287. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 288. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 289. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 290. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 291. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 292. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 293. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 294. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 295. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 296. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 297. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 298. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 299. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 300. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 301. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 302. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 303. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 304. NETHERLANDS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 305. NETHERLANDS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 306. NETHERLANDS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 307. NETHERLANDS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 308. NETHERLANDS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 309. NETHERLANDS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 310. NETHERLANDS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 311. NETHERLANDS THERAPEUTIC DRUG M

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Therapeutic Drug Monitoring market report include:
  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • Abbott Laboratories
  • Danaher Corporation
  • Siemens Healthineers AG
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Eurofins Scientific SE
  • Charles River Laboratories International, Inc.
  • ARKRAY, Inc.

Table Information